Affordable Access

Access to the full text

Interleukin-35 promotes progression of prostate cancer and inhibits anti-tumour immunity

  • Zhu, Jialin1
  • Wang, Yan2
  • Li, Dai3
  • Zhang, Haonan4
  • Guo, Zhi4
  • Yang, Xueling4
  • 1 Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China , Tianjin (China)
  • 2 The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, 310000, China , Hangzhou (China)
  • 3 Tianjin Geriatrics Institute, Tianjin Medical University General Hospital, Tianjin, 300000, China , Tianjin (China)
  • 4 Tianjin Medical University Cancer Institute and Hospital, Huan Hu West Road, Tianjin, 300060, China , Tianjin (China)
Published Article
Cancer Cell International
Springer (Biomed Central Ltd.)
Publication Date
Oct 07, 2020
DOI: 10.1186/s12935-020-01583-3
Springer Nature


BackgroundInterleukin-35 (IL-35) has been reported to play an important role in the progression of cancers. The role of IL-35 in prostate cancer (PCA) is not well understood. In this study, we investigated the effects of IL-35 on PCA and its immunoregulatory effect on PCA.MethodsThe protein and mRNA expression of IL-35 in PCA cells was detected by western blot and RT-PCR. The invasion and migration of cells were detected using transwell and wound‐healing assays. A CCK-8 assay was conducted to observe cell proliferation. In vivo, IL-35 plasma concentration was test by enzyme-linked immunosorbent assay. The role of IL-35 in tumour cell proliferation and angiogenesis of mice was detected by immunohistochemical stains. The mouse survival and tumour volumes were calculated, and lung metastasis rate was detected by HE staining. The modulatory effects of IL-35 on myeloid-derived inhibitory cells (MDSCs), regulatory T cells (Tregs), CD4+ T cells and CD8+ T cells from PCA mice were investigated by immunohistochemical stains and flow cytometry.ResultsHigh levels of IL-35 significantly promoted the migration, invasion and cell proliferation of PCA cells in vitro. IL-35 was associated with tumour growth, metastasis and poor prognosis in PCA mice. Additionally, high levels of IL-35 significantly increased the proportions of MDSCs and Tregs and decreased the proportions of CD4+ and CD8+ T cells in the spleen, blood and tumour microenvironment. The IL-35 neutralizing antibody played the opposite role.ConclusionsIL-35 contributed to the progression of PCA through promoting cell proliferation and tumour angiogenesis. IL-35 might limit the anti-tumour immune response by upregulating the proportions of Tregs and MDSCs and by reducing the proportions of CD4+ and CD8+ T cells. IL-35 might serve as a novel therapeutic target for PCA.

Report this publication


Seen <100 times